This meta-analysis designated that sGC modulators did not yield any mortality benefit in HF patients compared to placebo, and this finding was comparable to Moghaddam et al., though the authors did not mention change in NTpro-BNP levels and EQ-5D in comparison to KCCQ29. The gene discussed is SGCB; the disease is hydrops fetalis.